200 related articles for article (PubMed ID: 25894754)
1. Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists.
Altun A; Yildirim K; Ozdemir E; Bagcivan I; Gursoy S; Durmus N
J Physiol Sci; 2015 Sep; 65(5):407-15. PubMed ID: 25894754
[TBL] [Abstract][Full Text] [Related]
2. The effects of endocannabinoid receptor agonist anandamide and antagonist rimonabant on opioid analgesia and tolerance in rats.
Altun A; Ozdemir E; Yildirim K; Gursoy S; Durmus N; Bagcivan I
Gen Physiol Biophys; 2015 Oct; 34(4):433-40. PubMed ID: 26374993
[TBL] [Abstract][Full Text] [Related]
3. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
da Fonseca Pacheco D; Klein A; de Castro Perez A; da Fonseca Pacheco CM; de Francischi JN; Duarte ID
Br J Pharmacol; 2008 Jul; 154(5):1143-9. PubMed ID: 18469844
[TBL] [Abstract][Full Text] [Related]
4. Mu-opioid and CB1 cannabinoid receptors of the dorsal periaqueductal gray interplay in the regulation of fear response, but not antinociception.
Godoi MM; Junior HZ; da Cunha JM; Zanoveli JM
Pharmacol Biochem Behav; 2020 Jul; 194():172938. PubMed ID: 32376258
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid CB
Weresa J; Pędzińska-Betiuk A; Kossakowski R; Malinowska B
Pharmacol Rep; 2019 Feb; 71(1):82-89. PubMed ID: 30500553
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents.
Bi GH; Galaj E; He Y; Xi ZX
Addict Biol; 2020 Jul; 25(4):e12783. PubMed ID: 31215752
[TBL] [Abstract][Full Text] [Related]
7. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
8. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
9. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Burgos E; Pascual D; Martín MI; Goicoechea C
Eur J Pain; 2010 Jan; 14(1):40-8. PubMed ID: 19318283
[TBL] [Abstract][Full Text] [Related]
11. The cannabinoid CB
Iyer V; Slivicki RA; Thomaz AC; Crystal JD; Mackie K; Hohmann AG
Eur J Pharmacol; 2020 Nov; 886():173544. PubMed ID: 32896549
[TBL] [Abstract][Full Text] [Related]
12. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.
Silva NR; Gomes FV; Fonseca MD; Mechoulam R; Breuer A; Cunha TM; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):369-377. PubMed ID: 28720466
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid system involves in the analgesic effect of protocatechuic acid.
Dikmen DY; Okcay Y; Arslan R; Bektas N
Daru; 2019 Dec; 27(2):605-612. PubMed ID: 31325037
[TBL] [Abstract][Full Text] [Related]
14. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
15. Opioid-sparing effects of cannabinoids on morphine analgesia: participation of CB
Chen X; Cowan A; Inan S; Geller EB; Meissler JJ; Rawls SM; Tallarida RJ; Tallarida CS; Watson MN; Adler MW; Eisenstein TK
Br J Pharmacol; 2019 Sep; 176(17):3378-3389. PubMed ID: 31218677
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats.
Sagar DR; Kelly S; Millns PJ; O'Shaughnessey CT; Kendall DA; Chapman V
Eur J Neurosci; 2005 Jul; 22(2):371-9. PubMed ID: 16045490
[TBL] [Abstract][Full Text] [Related]
17. Dissociation between morphine-induced spinal gliosis and analgesic tolerance by ultra-low-dose α2-adrenergic and cannabinoid CB1-receptor antagonists.
Grenier P; Wiercigroch D; Olmstead MC; Cahill CM
Behav Pharmacol; 2018 Apr; 29(2 and 3-Spec Issue):241-254. PubMed ID: 29481424
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
19. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
20. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.
Elmas P; Ulugol A
J Neural Transm (Vienna); 2013 Nov; 120(11):1533-8. PubMed ID: 23784345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]